12 studies were found.

1.		No longer recruiting	Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer Conditions: Male Breast Cancer; stage II breast cancer; stage IIIA breast cancer
2.		Completed	Aminocamptothecin in Treating Patients With T-cell Lymphoma Conditions: stage III cutaneous T-cell lymphoma; stage IV cutaneous T-cell lymphoma; recurrent cutaneous T-cell lymphoma; stage II cutaneous T-cell lymphoma
3.		No longer recruiting	Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Condition: stage IIIA non-small cell lung cancer
4.		No longer recruiting	Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
5.		Suspended	High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Condition: unspecified adult solid tumor, protocol specific
6.		No longer recruiting	Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Conditions: Lung Cancer; Renal Cell Cancer; Head and Neck Cancer; Melanoma; Thyroid Cancer; Eye Cancer; Kidney Cancer
7.		Recruiting	Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer Conditions: stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
8.		Completed	Perillyl Alcohol in Treating Patients With Refractory Cancer Conditions: Leukemia; Lymphoma
9.		Completed	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Conditions: lip and oral cavity cancer; Oropharyngeal Cancer; Head and Neck Cancer
10.		No longer recruiting	Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
11.		Recruiting	Topotecan and Bortezomib in Treating Patients With Metastatic or Unresectable Cancer Condition: unspecified adult solid tumor, protocol specific
12.		No longer recruiting	Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer Condition: unspecified adult solid tumor, protocol specific